COFEPRIS

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico's federal regulatory authority for medicines, medical devices, food, cosmetics, pesticides, tobacco + occupational + environmental health risks. COFEPRIS is a decentralized organ of the Secretaría de Salud, established by Presidential Decree of 5 July 2001 + operating under the authority of the Ley General de Salud (LGS — General Health Law). COFEPRIS's headquarters is in Mexico City, with regional offices across Mexico's 32 federal entities + approximately 2,400 staff.

The COFEPRIS ecosystem includes:

• Comisión de Autorización Sanitaria (CAS) — drug + device + cosmetic + food marketing authorisations + clinical-trial authorisations.
• Comisión de Operación Sanitaria (COS) — inspection, sanitary verification + enforcement; GMP / GDP inspectorate.
• Comisión de Evidencia y Manejo de Riesgos (CEMAR) — risk evaluation, scientific advice + pharmacovigilance signal management.
• Comisión de Fomento Sanitario (CFS) — regulatory promotion, outreach + industry engagement.
• Comisión de Control Analítico y Ampliación de Cobertura (CCAYAC) — federal control laboratory + analytical reference + lot release.
• Centro Nacional de Farmacovigilancia (CNFV) — National Pharmacovigilance Centre, operating Mexico's pharmacovigilance database, integrated with WHO VigiBase via UMC Uppsala.
• Centro Integral de Servicios (CIS) — single-window service centre for submissions + administrative procedures.
• DIGIPRiS — COFEPRIS's digital submission portal for trámites (procedures), launched 2018 + progressively expanded.

Legal foundations are the Ley General de Salud (LGS, 1984 with extensive amendments), the Reglamento de Insumos para la Salud (RIS — Health Inputs Regulation), the Reglamento de la Ley General de Salud en Materia de Investigación para la Salud, the Reglamento de Control Sanitario de Productos y Servicios + a substantial body of Normas Oficiales Mexicanas (NOMs — official Mexican standards) covering GMP (NOM-059), medical-device QMS (NOM-241), labelling, pharmacovigilance (NOM-220) + clinical trials (NOM-012).

COFEPRIS is a PIC/S Member since January 2018, a PAHO/WHO designated Reference Regulatory Authority (NRAr) at Maturity Level IV — the highest WHO Global Benchmarking Tool level, achieved 2014 + reconfirmed 2020 + 2024. As of 2024 COFEPRIS is one of only six WHO ML4 NRAs worldwide (alongside Australia TGA, Switzerland Swissmedic, Saudi Arabia SFDA — recently confirmed + others). COFEPRIS is an ICH Observer, an IMDRF Affiliate Member, an active ICMRA participant + a founding member of the Pan American Network for Drug Regulatory Harmonization (PANDRH).

The Equivalence-Based Registration pathway (also called Reliance, Equivalencia or Article 222 BIS pathway) is COFEPRIS's flagship work-sharing mechanism, established under Article 222 BIS of the Ley General de Salud + operationalised by Acuerdo 31/01/2020 + subsequent COFEPRIS guidance. It is one of the most aggressive reliance pathways operated by any major regulator.

• Designated equivalent agencies — FDA, EMA (centralised procedure), Health Canada, TGA, Swissmedic, PMDA, MHRA + COFEPRIS-designated EU national authorities; periodically reviewed + updated.
• 60 working day clock — substantially shorter than the 240 wd Full Review for new chemical entities or 180 wd for biotechnologicals.
• Full reference-regulator dossier required — applicants provide the full assessment report, product information + supporting documentation from the reference regulator; COFEPRIS conducts a Mexican-specific overlay assessment focused on Mexican labelling, pharmacovigilance + post-marketing commitments.
• Acceptable for new MAs + Renewals + Variations — equivalence applies across the product lifecycle.
• Article 222 BIS implementation has substantially reduced approval clocks — for many companies, the equivalence pathway is the default route for entering the Mexican market.
• PANDRH harmonisation — equivalence pathway leverages PANDRH technical work + facilitates simultaneous filings in Mexico + Central American + Andean countries.
• Limitations — equivalence does not apply to controlled substances, certain biologicals + products without acceptable reference-regulator approval; full Mexican assessment is required in those cases.
• Post-equivalence variations follow the standard Modificaciones a las Condiciones de Registro framework — variation tiering applies to equivalence-approved products.
• Equivalence pathway interacts with PAHO reliance + PANDRH harmonisation — Mexican Equivalence MAs are themselves accepted by many Central + South American regulators as reliance evidence.

• Class I — Lowest risk; COFEPRIS Class I registration with reduced data requirements; many Class I devices benefit from simplified registration via DIGIPRiS.
• Class II — Moderate risk; substantively equivalent to EU MDR Class IIa / IIb with full technical + QMS evidence.
• Class III — Highest risk; substantively equivalent to EU MDR Class III with comprehensive clinical-evaluation + post-market surveillance requirements.
• IVD classification — substantively aligned with IVDR principles with COFEPRIS-specific implementation per NOM-241.
• NOM-241-SSA1-2021 — Buenas Prácticas de Fabricación de Dispositivos Médicos; Mexican QMS standard substantively aligned with ISO 13485:2016 + with COFEPRIS-specific elements.
• Reference-regulator basis — COFEPRIS recognises CE marking under EU MDR / IVDR, FDA 510(k) / De Novo / PMA, Health Canada, TGA + PMDA as evidence supporting Mexican registration via Equivalence pathway extended to devices.
• MDSAP recognition — COFEPRIS accepts MDSAP audit reports as QMS evidence; full reliance for QMS-evidence purposes.
• Mexican Responsable Sanitario — foreign manufacturers must designate a Mexican-registered Responsable Sanitario (Health Responsible) who holds professional pharmaceutical / medical credentials + handles regulatory + pharmacovigilance interactions with COFEPRIS.
• Mexican Authorised Representative + Licencia Sanitaria — required for all Mexican-resident manufacturers, importers + wholesalers; foreign manufacturers must operate through a Mexican-licensed entity.
• Clinical evaluation — Class II + III typically require Mexican clinical-investigation data or accepted reference-regulator clinical evidence; Class I may use literature + comparator data.
• Field Safety Corrective Action (FSCA) — COFEPRIS FSCA + Field Safety Notice (FSN) framework substantively aligned with EU MDR + IMDRF.
• UDI rollout — Mexico is progressively implementing UDI for medical devices following IMDRF UDI Guidance + with reference to FDA UDI + EU MDR UDI requirements.

• NOM-059-SSA1-2015 — Mexican GMP standard substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10; covers manufacture of medicinal products including biologics + APIs.
• NOM-176-SSA1-1998 — Mexican GMP standard for APIs + active pharmaceutical ingredients; complements NOM-059 + aligned with ICH Q7.
• PIC/S Member since Jan 2018 — full reliance with all PIC/S members; substantial milestone for Mexican pharma regulatory credibility.
• Reference Regulator network — COFEPRIS recognises FDA, EMA + EU national, Health Canada, TGA, MHRA, Swissmedic, PMDA + others as reference regulators for both product authorisation reliance + GMP-evidence reliance.
• Overseas inspections — COFEPRIS conducts overseas inspections of foreign sites supplying Mexico; risk-based programme prioritising new MA applications, biologics, sterile products + APIs; substantial expansion of overseas-inspection capacity since 2018.
• Data integrity — COFEPRIS data-integrity expectations substantively aligned with PIC/S PI 041 + MHRA + WHO + FDA; ALCOA+ + audit-trail + computerised-systems requirements.
• MDSAP — COFEPRIS accepts MDSAP audit reports as Mexican device QMS evidence.
• Tercero Autorizado (Third Party Authorized) — COFEPRIS-authorised Mexican entities conducting GMP audits + bioequivalence studies + clinical-trial monitoring on behalf of MAHs; controlled programme with periodic re-authorisation.
• Inspection findings + remediation — COFEPRIS Inspection Reports + Suspensión de Actividades (suspension of activities) + manufacturing-licence withdrawal; published market actions on COFEPRIS portal.
• Licencia Sanitaria — COFEPRIS-issued licences for Mexican-resident manufacturers, importers, wholesalers + retail pharmacies; required for all drug-handling activities + periodically renewed + inspected.
• GDP — Buenas Prácticas de Distribución per NOM-059 + supplementary COFEPRIS guidance; substantively aligned with PIC/S GDP Guide + EU GDP Guidelines.

• Centro Nacional de Farmacovigilancia (CNFV) — COFEPRIS pharmacovigilance unit operating Mexico's national pharmacovigilance database; integrated with WHO VigiBase via UMC Uppsala since 1999.
• NOM-220-SSA1-2016 — Mexican pharmacovigilance standard substantively aligned with ICH E2A / E2B / E2C / E2D / E2E + WHO GVP modules; covers ICSR + PSUR + RMP + signal detection.
• ICSR reporting — serious unexpected ADRs within 15 calendar days; non-serious in periodic reports + PSURs per ICH E2D + NOM-220.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle; submitted to CNFV.
• Risk Management Plan (RMP) — required for new active substances + biocomparables + significant indications; per ICH E2E + NOM-220.
• Responsable Sanitario para Farmacovigilancia — Mexican pharmacovigilance contact required for Mexican MAH; substantively aligned with EU QPPV role.
• Pharmacovigilance Master File — equivalent to EU PSMF for new MAs + on-request inspection availability.
• Medical device adverse-event reporting — COFEPRIS device-vigilance framework with Tecnovigilancia programme + FSCA + FSN substantively aligned with EU MDR vigilance + IMDRF.
• Healthcare-professional + consumer reporting — COFEPRIS online reporting via DIGIPRiS + Notimed mobile app + dedicated CNFV channels.
• Recall — COFEPRIS-coordinated recall framework with COS + Mexican distributors + healthcare institutions + traceability support.
• Drug Shortages — COFEPRIS drug-shortage monitoring programme; MAHs required to report shortages of essential medicines per Cuadro Básico Sectorial.
• COFEPRIS Safety Communications — Alertas Sanitarias + Notas Informativas published on COFEPRIS portal + distributed to healthcare professionals + via traditional + social media.

• PIC/S Member since Jan 2018 — full GMP reliance with all PIC/S members including FDA + EMA / EU national authorities + Health Canada + TGA + Swissmedic + PMDA + MFDS + SFDA + ANVISA + many others.
• PAHO/WHO Reference Regulatory Authority (NRAr) at Maturity Level IV — highest WHO Global Benchmarking Tool level; one of only six WHO ML4 NRAs worldwide as of 2024; reconfirmed 2014, 2020 + 2024.
• ICH Observer working toward Regulatory Membership — COFEPRIS progressively adopting ICH guidelines + participating in ICH Working Groups.
• IMDRF Affiliate Member — active on UDI, SaMD, AI / ML, QMS work products + Mexican adoption of IMDRF outputs.
• ICMRA — active member contributing on pandemic preparedness, supply chain, regulatory innovation + reliance.
• PANDRH leadership — founding member + co-leader of the Pan American Network for Drug Regulatory Harmonization; PANDRH Technical Working Groups on GMP, GCP, Pharmacovigilance, Vaccines, Biotherapeutics, Biocomparables, Medical Devices + Regulatory Reliance.
• PAHO Regional Reliance — COFEPRIS Equivalence-pathway decisions + GMP inspections are routinely accepted as reliance evidence by Central American + Andean Community regulators; COFEPRIS hosts PAHO regional training + capacity building.
• Bilateral MoUs — COFEPRIS holds MoUs with FDA, EMA, Health Canada, TGA, MHRA, Swissmedic, ANVISA, INVIMA, ANMAT + many others; tight cooperation on inspections + information exchange.
• USMCA / T-MEC alignment — Mexico's regulatory framework is influenced by USMCA pharmaceutical + medical-device provisions; tri-lateral coordination with FDA + Health Canada through trade + regulatory mechanisms.
• Vaccines + COVID-19 response — COFEPRIS Emergency Use Authorization framework + accelerated review for COVID-19 vaccines + therapeutics demonstrated PIC/S-Member-level capability; COVAX participation + WHO vaccine programmes.

• Responsable Sanitario not properly designated or credentialed — application rejected at DIGIPRiS intake or post-approval compliance failure.
• Licencia Sanitaria not in place or scope mismatched — market placement blocked.
• Equivalence pathway eligibility misjudged — applicants applying for Equivalence with non-designated reference regulator or incomplete reference dossier; clock reverts to Full Review.
• Spanish-language labelling + IFU non-compliant — Mexican labelling requires Spanish + specific COFEPRIS-required content + warnings + Responsable Sanitario contact details + Cuadro Básico identification.
• DIGIPRiS eCTD submission errors — module structure non-compliance, missing Module 1 Mexican-specific elements, technical-format failures.
• Tercero Autorizado bioequivalence study quality issues — bioequivalence study at non-authorised centre or with methodology deficiencies; generic registration delayed or rejected.
• NOM-220 pharmacovigilance reporting timelines missed — Responsable Sanitario para Farmacovigilancia enforcement.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data; PIC/S-level expectations apply post-2018.
• Sterile / aseptic process gaps — COFEPRIS inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• MDSAP audit-report packaging gap — COFEPRIS accepts MDSAP but requires the full audit report + non-conformity closures.
• NOM-241 device QMS gaps — Mexican-specific elements beyond ISO 13485 not addressed.
• Clinical-trial CTA + Comité de Ética en Investigación coordination gap per NOM-012.
• Variations tier misclassification — applicants treating major variations as minor; rework + clock reset.
• Cuadro Básico Sectorial misalignment — products targeting Mexican public-sector procurement (IMSS, ISSSTE, INSABI) without proper Cuadro Básico listing.
• PSUR not aligned with International Birth Date — Mexican PSUR cycle out of sync with EMA PSUR / FDA PADER submissions.

V5 Ultimate provides the operational infrastructure Mexican + foreign-supplier sites need for LGS + RIS + NOM-059 + NOM-241 + NOM-220 + COFEPRIS Implementing guidance compliance + COFEPRIS readiness.

• COFEPRIS GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + COFEPRIS data-integrity-expectation alignment.
• Responsable Sanitario + Licencia Sanitaria workflow — Responsable Sanitario designation + credential tracking, Licencia Sanitaria scope management, foreign-manufacturer QMS-evidence packaging.
• DIGIPRiS submission packaging — eCTD-aligned dossier structure with Mexican Module 1 specifics, reference-regulator assessment-report packaging for Equivalence pathway.
• Equivalence pathway workflow — reference-regulator assessment-report packaging, designated-agency eligibility verification, Mexican-specific overlay assessment, 60-wd clock tracking.
• Reference-regulator bridging — FDA / EMA / Health Canada / TGA / MHRA / Swissmedic / PMDA assessment-report packaging for COFEPRIS Equivalence pathway; Mexican-specific data overlay.
• Medical Device + IVD registration workflow — Class I / II / III + IVD classification, MDSAP + ISO 13485 + NOM-241 audit-report packaging, COFEPRIS device-registration tracking.
• Tercero Autorizado management — bioequivalence study + GMP audit + clinical-monitoring engagement workflow with COFEPRIS-authorised third parties.
• Spanish + bilingual labelling + IFU — Mexican-language artwork workflow with two-person review + e-signature; COFEPRIS-required elements + warnings + storage conditions + Responsable Sanitario details + Cuadro Básico identification.
• CNFV pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Responsable Sanitario para Farmacovigilancia workflow + Mexican Pharmacovigilance Master File.
• Medical device tecnovigilancia — FSCA + FSN reporting per COFEPRIS framework + IMDRF alignment.
• PANDRH + PAHO regional bridging — for companies operating across Latin America, V5 surfaces COFEPRIS-decision reuse + PANDRH-harmonised dossier elements + Central American + Andean Community filing workflows.
• Cuadro Básico Sectorial — for products targeting Mexican public-sector procurement (IMSS, ISSSTE, INSABI), V5 surfaces Cuadro Básico listing workflow + public-procurement tender preparation.